Early treatment with dexamethasone intravitreal implants in diabetic macular edema: Naïve versus refractory patients
- 12 June 2021
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 32 (3) , 1619-1626
Abstract
To assess the efficacy and safety of dexamethasone 0.7 mg implants (DEX-I) in patients with diabetic macular edema (DME) either naïve to therapy or refractory to anti-VEGF treatment, in a single-center, real-world setting. Patients diagnosed with DME and treated with DEX-I were retrospectively enrolled in the study and split in two groups: naïve (Group 1, n = 64) and refractory (Group 2, n = 64) to treatment. Patients were evaluated at baseline, at 1 month, and every 3 months after each DEX-I implant. Main outcome measures were change in best-corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline to follow-up visits. Significant improvements in BCVA were observed in treatment-naïve patients at 6 months following the first and second DEX-I injection (p = 0.0023 and p = 0.0063, respectively), with significant reductions in mean CMT at 6 months after all DEX implants. In treatment-refractory patients, mean CMT was significantly reduced from baseline to 6 months (p < 0.05) after all DEX-I injections, although no changes were observed in BCVA. DEX-I improved visual acuity and macular edema mostly in treatment-naïve patients, suggesting DEX-I may be a viable first-line treatment option in DME.Keywords
Funding Information
- Allergan SpA
- ICMJE
This publication has 20 references indexed in Scilit:
- Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edemaBMC Ophthalmology, 2019
- Corticosteroids for diabetic macular edemaTaiwan Journal of Ophthalmology, 2019
- DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYESRetina, 2019
- Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision ImpairmentJAMA Ophthalmology, 2018
- INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDYRetina, 2016
- Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision ImpairmentJAMA Ophthalmology, 2016
- Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD studyBMC Ophthalmology, 2015
- Dexamethasone Implants in Patients with Naïve or Refractory Diffuse Diabetic Macular EdemaOphthalmologica, 2015
- Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular EdemaOphthalmology, 2014
- TREATMENT OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR–RESISTANT DIABETIC MACULAR EDEMA WITH DEXAMETHASONE INTRAVITREAL IMPLANTRetina, 2014